Screener
Rigel Pharmaceuticals RIGL Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | As of / March 31, 2026 | As of / December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $24,411 | $40,580 |
| Short-term investments | 122,273 | 114,375 |
| Accounts receivable, net | 49,945 | 51,763 |
| Inventories | 11,652 | 11,506 |
| Prepaid and other current assets | 25,746 | 21,942 |
| Total current assets | 234,027 | 240,166 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's short-term investments?
- Rigel Pharmaceuticals (RIGL) reported short-term investments of $122.27M in Q1 2026.
- How has Rigel Pharmaceuticals's short-term investments changed year-over-year?
- Rigel Pharmaceuticals's short-term investments increased by 289.8% year-over-year, from $31.37M to $122.27M.
- What is the long-term trend for Rigel Pharmaceuticals's short-term investments?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's short-term investments has grown at a 33.5% compound annual growth rate (CAGR), from $26.95M to $114.38M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Rigel Pharmaceuticals's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude